ReviewExpert review of vaccines2018

The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.

Seth M PollackPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.